caution larry

Hi, I’m Kim! This site provides a little insight to my journey of being diagnosised with Remitting Relapsing Multiple Sclerosis on October 26th 2004. I review books and documentaries, post MS-related news, and share my photos.

Subscribe (RSS)

no larry

My bloglines



November 2004
December 2004
January 2005
February 2005
March 2005
April 2005
May 2005
June 2005
July 2005
August 2005
September 2005
October 2005
November 2005
December 2005
January 2006
February 2006
March 2006
April 2006
May 2006
June 2006
July 2006
August 2006
September 2006
October 2006
November 2006
December 2006
January 2007
February 2007
March 2007
April 2007
May 2007
June 2007
July 2007
August 2007
September 2007
October 2007
November 2007
December 2007
January 2008
February 2008
March 2008
April 2008
May 2008
June 2008
July 2008
August 2008
September 2008
October 2008
November 2008
December 2008
January 2009
February 2009
March 2009
April 2009
May 2009
June 2009
July 2009
August 2009
September 2009
October 2009
November 2009
December 2009
January 2010
February 2010
March 2010
May 2010
June 2010
July 2010
September 2010
November 2011


Thursday, July 19, 2007
TRIMESTA (oral estriol) trial starting and fundraising
TRIMESTA (oral estriol) trial starting

Well, that didn't seem to take long for this type of therapy to keep moving forward. This is the one for women only though. Sorry guys. "Dr. Charles Bisgaier, Pipex's President, stated, "To our knowledge, this is the first gender-specific, oral, potentially disease-modifying agent that has entered later-stage clinical trials for the treatment of MS." Dr. Bisgaier went onto say, "Given the convenience of an oral drug therapy, such as TRIMESTA, we have received a lot of positive patient interest in this study and hope to continue enrolling at this positive rate." The Phase II/III clinical study is a double-blind, placebo-controlled trial that will take place at seven sites in the US and will enroll up to 150 female MS patients. Investigators will administer TRIMESTA along with COPAXONE, an FDA approved therapy for MS to women between the ages of 18-50 who have been recently diagnosed with relapsing-remitting MS. Previous Phase II Clinical Trial Results in Relapsing Remitting Multiple Sclerosis TRIMESTA (oral estriol) has completed an initial 22-month, single-agent, crossover Phase II clinical trial in the US for the treatment of MS in relapsing remitting patients, with highly encouraging results. The results showed the total volume and number of enhancing pathogenic myelin lesions (established neuroimaging measurements of disease activity in MS) decreased during the treatment period as compared to a six-month pretreatment baseline period. The median total enhancing lesion volumes decreased by 79 percent (p=0.02) and the number of lesions decreased by 82 percent (p=0.09) within the first three months of treatment with TRIMESTA. Following a six-month drug holiday during which the patients weren't on any drug therapies, TRIMESTA therapy was reinitiated during a four-month retreatment phase of this clinical trial. The relapsing-remitting MS patients again demonstrated a decrease in enhancing lesion volumes of 88 percent (p=0.008) and a decrease in the number of lesions by 48 percent (p=0.04) compared with original baseline scores (1),(2).

If you donated to my fundraising efforts

Here is where the money went! I'm pretty happy about that. "Two Ottawa researchers have been awarded a $2.4-million grant for their work in fighting multiple sclerosis, a chronic and often disabling disease of the brain and spinal cord. The Multiple Sclerosis Society of Canada recently awarded the money to a team led by Dr. Harry Atkins and Dr. Mark Freedman, who will continue a closely watched clinical trial involving an experimental bone marrow stem cell transplant therapy. That research has seen MS symptoms slowed in some patients and even some improvements in the ability to see and walk. "The idea behind this clinical trial is to replace the diseased immune system with a new one derived from the patient's own bone marrow stem cells," said Atkins, a scientist at the Ottawa Health Research Institute, and a bone marrow transplant specialist at the Ottawa Hospital. "First, we purify and freeze the patient's stem cells, then we use strong chemotherapy to destroy their existing immune system," he said. "We then transplant the purified stem cells back into the patient. "It takes time, but eventually these stem cells will form a completely new immune system - one that does not attack the brain and spinal cord - we hope."